Purdue Pharma: The First Plea and the Prescriptions That Followed

The Purdue Pharma fraud settlement was a federal resolution of more than $8 billion over opioid marketing and kickbacks, announced in 2020. The history begins on May 10, 2007, when Purdue Frederick and three executives agreed to pay $634,515,475 over false OxyContin marketing. The company had promoted the drug as less addictive, less subject to abuse and less likely to cause withdrawal than other pain medications. Warnings had come from its own sales force. The conduct Purdue Pharma later admitted began in that same month.

The 2007 announcement said there was no medical research supporting those comparative claims. Purdue Frederick pleaded guilty to fraudulent misbranding. Its president, chief legal officer and former chief medical officer pleaded guilty to misdemeanor misbranding.

The United States Attorney described warnings from inside the business:

The officers’ financial obligations included approximately $34.5 million in compensation they had received from Purdue and a $5,000 fine each. The court’s account of their admissions says they had authority to prevent or correct the false statements. That is the responsibility at the center of the corporate officers’ case.

An employee who carried out instructions can still be a whistleblower. Who designed the campaign, who directed it and what you were told to do are matters our whistleblower experts work through with you.

May 2007 and the Conduct That Continued

Purdue Pharma’s later admission covered a scheme that began in the month of Purdue Frederick’s plea. In its November 24, 2020 plea announcement, the Justice Department said the admitted scheme ran “from May 2007 through at least March 2017”.

Purdue told the Drug Enforcement Administration that it maintained an effective program to stop its opioids from being diverted to improper use. It continued marketing to more than 100 health care providers it had good reason to believe were diverting them.

Those prescriptions also served another purpose. Purdue included prescriptions from doctors it had reason to believe were engaged in diversion in the data it reported to obtain higher manufacturing quotas. The company used the suspect prescribing to support permission to manufacture more. It also admitted facilitating the dispensing of opioids, including OxyContin, without a legitimate medical purpose or lawful prescriptions.

For someone in sales or compliance, this opioid marketing fraud connects decisions that can sit in different departments. The provider attracting concern inside the company could remain a marketing target. The same provider’s prescriptions could then help justify a larger production allowance.

Speaker Payments Bought More Prescriptions

From June 2009 through March 2017, Purdue paid two doctors through its speaker program to induce them to write more prescriptions for its opioids. Purdue admitted that purpose in its plea. The separate civil settlement also covered broader allegations about payments for educational talks and consulting.

A speaker program kickback can turn on what the company expects from the person receiving the fee. Purdue admitted buying more prescribing from the speakers themselves. The payment record and the prescribing record belong together.

The same expectation appears in a whistleblower complaint against Forest Pharmaceuticals. The complaint quoted a manager questioning payment to a speaker who was writing too few prescriptions:

The question measures the speaker by the prescriptions she writes. It says nothing about the quality of the talk.

A 2012 Nordic Cochrane Centre review, Corporate Crime in the Pharmaceutical Industry Is Common, Serious and Repetitive, identified kickbacks alongside misleading research and concealed harms in cases involving major drug companies. Its finding places prescriber payments within a recurring pattern of pharmaceutical misconduct. Purdue’s admission supplies the specific transaction here: speaker fees intended to produce prescriptions.

The Payment Reached the Prescribing Screen

From April through December 2016, Purdue paid Practice Fusion, an electronic health records company, for referring, recommending and arranging orders for OxyContin, Butrans and Hysingla. These were Purdue’s extended-release opioid products. The payment to the software company was another admitted kickback channel.

An electronic health record sits where the clinician makes and records treatment decisions. In Practice Fusion’s own case, the company admitted accepting opioid-company kickbacks for clinical decision support alerts. That places the paid influence inside the software a prescriber uses during care.

The ordinary drug distribution chain runs from manufacturer to wholesaler to dispenser. This payment bought influence over what the clinician prescribed. Payments through an electronic health records vendor can therefore leave their most useful evidence in a vendor contract, the rules governing an alert and the records of its implementation. Our work is to connect what the manufacturer paid for with what the clinician actually saw.

The Purdue Pharma Fraud Settlement and Its Payment Terms

On October 21, 2020, the Justice Department announced the Purdue Pharma fraud settlement as a criminal and civil resolution. On November 24, Purdue Pharma pleaded guilty to the fraud and kickback conspiracies.

Purdue agreed to a $3.544 billion criminal fine and $2 billion in forfeiture. The cash portion of the forfeiture was $225 million. The October announcement placed that payment at the effective date of the bankruptcy. The November plea announcement specified payment within three business days after entry of the judgment of conviction.

The government also agreed to credit up to $1.775 billion against the forfeiture for value delivered to state and local governments through a public benefit company.

The civil settlement gave the United States a $2.8 billion claim in Purdue’s bankruptcy.

The Civil Allegations Followed the Prescription to the Pharmacy

The civil settlement covered allegations that Purdue caused false claims to federal healthcare programs from 2010 through 2018. The programs included Medicare, Medicaid and TRICARE. The government alleged that Purdue promoted opioids to providers it knew were prescribing them for unsafe, ineffective and medically unnecessary uses.

The allegation about one prescriber shows what that meant inside the sales operation. The government said Purdue learned that the doctor was prescribing dangerously high OxyContin doses, yet sales representatives met with the doctor more than 300 times.

The civil settlement also covered a specialty pharmacy kickback allegation beyond the admitted doctor and software payments. Purdue allegedly contracted with certain specialty pharmacies to fill opioid prescriptions that other pharmacies had rejected as potentially lacking medical necessity.

Here the prescription already existed. A pharmacy had questioned it. The alleged arrangement gave it another route to a fill. The original rejection, communications about medical necessity and the replacement pharmacy’s contract can explain what the manufacturer was buying.

Purdue allegedly drove prescriptions that put patients at risk and left taxpayers paying for medically unnecessary drugs. A manufacturer can face a False Claims Act case for causing those bills even when a pharmacy submits them.

The Owners’ Separate Civil Settlement

The October 2020 announcement also described a separate $225 million civil settlement with members of the family that owned Purdue. The government alleged that they knew in 2012 that the legitimate market for Purdue’s opioids had contracted, but asked executives to recover lost sales and increase market share.

According to the government’s allegations, they approved Evolve to Excellence, a marketing program beginning in 2013. Sales representatives intensified their attention to extreme, high-volume prescribers who already wrote 25 times as many OxyContin prescriptions as their peers. The alleged response to a shrinking legitimate market was to press harder on its most prolific prescribers.

The settlement also addressed allegations that, from approximately 2008 through 2018, Purdue transferred assets to family holding companies and trusts at the owners’ request to hinder future creditors.

The federal resolutions gave no individual a criminal release and gave no company executive or employee a civil release.

Purdue’s Bankruptcy and the End of Opioid Marketing

The original resolution required Purdue to cease operating in its existing form and emerge as a public benefit company or an entity with a similar public mission. Its proceeds would support state and local opioid abatement programs. The proposed forfeiture credit depended on the value that structure delivered.

On April 28, 2026, the Justice Department reported a court order covering over $5 billion in criminal financial obligations. That was the fine and forfeiture described above. It also required Purdue to host a public repository of documents relating to the criminal charges.

A separate national settlement with Purdue and its owners reached a later milestone. In its May 1, 2026 announcement, the Pennsylvania Attorney General said the $7.4 billion settlement had become legally effective. It provided funding for communities, individual victims and other groups that had filed bankruptcy claims. Community funding for addiction treatment, prevention and recovery would run over fifteen years.

That announcement described more than $1.5 billion from the owners and approximately $900 million from Purdue being paid that day.

Pennsylvania said Purdue’s manufacturing operations transferred that day to Knoa Pharma LLC. The settlement barred the former owners from selling opioids in the United States and barred Knoa from marketing them. It provided an independent monitor and a board with no connection to Purdue. It also provided for making public more than 30 million documents related to the opioid business.

The Department of Health and Human Services’ Office of Inspector General lists Purdue Pharma’s federal health program exclusion as effective July 20, 2026.

What Evidence Is Needed to Prove Fraud?

In this case, the evidence connects the marketing decision, the payment or representation, and the prescription or fill it was meant to produce. An insider may know why a flagged provider stayed on a call list, what sales management expected from a speaker, who approved a software recommendation or why a rejected prescription went to another pharmacy.

Those are different views of the same business. A sales representative may recognize the instructions and prescribing targets. A compliance employee may recognize the provider concerns and the data sent to the government. Someone at a software vendor or pharmacy may see the contract that explains a decision the manufacturer wanted made. We work with pharmaceutical whistleblowers to connect those decisions to the claims government programs paid.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The Instructions You Saw Matter

If you know how a sales target became a speaker payment, a prescribing alert or a pharmacy arrangement, speak to one of our whistleblower experts. We build your strongest whistleblower case with you and bring in pharmaceutical fraud whistleblower lawyers who understand manufacturer payments and government prescription claims. We stay beside you as your knowledge of the business becomes the evidence behind the case.